CRISPR Therapeutics
CRSP
484 hedge funds and large institutions have $4.1B invested in CRISPR Therapeutics in 2024 Q1 according to their latest regulatory filings, with 75 funds opening new positions, 159 increasing their positions, 138 reducing their positions, and 56 closing their positions.
34% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 56
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
21% more call options, than puts
Call options by funds: $256M | Put options by funds: $212M
17% more capital invested
Capital invested by funds: $3.5B → $4.1B (+$594M)
15% more repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 138
3% more funds holding
Funds holding: 472 → 484 (+12)
0.23% less ownership
Funds ownership: 70.47% → 70.24% (-0.23%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$122M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$99.5M |
| 3 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$75.1M |
| 4 |
CIM
Contrarius Investment Management
St. Helier,
Jersey
|
+$34.6M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$30M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$64.9M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$48.9M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$27.1M |
| 4 |
Jane Street
New York
|
-$21.5M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$20.1M |
CRSP Hedge Fund Activity: Q1 2024 in Review
484 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2024, worth a combined $4.1B — up 17% from $3.5B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new CRSP positions and 56 closed out — a net gain of 19 holders — while 159 added to existing stakes and 138 trimmed.
The largest buyer was Capital International Investors, adding an estimated $122M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $64.9M.
- 484 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2024, up from 472 in Q4 2023.
- Funds reported $4.1B of CRISPR Therapeutics stock for Q1 2024, up 17% quarter-over-quarter.
- 75 funds opened new CRISPR Therapeutics positions in Q1 2024 and 56 closed out, a net change of +19 holders.
- The largest CRISPR Therapeutics buyer in Q1 2024 was Capital International Investors, an estimated $122M added.
- The largest CRISPR Therapeutics seller in Q1 2024 was T. Rowe Price Investment Management, an estimated $64.9M sold.
Based on aggregated 13F filings for Q1 2024.